Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
D 0.79 -7.18% -0.06
BLRX closed down 7.18 percent on Thursday, July 18, 2024, on 1.72 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New Uptrend Bullish -7.18%
Pocket Pivot Bullish Swing Setup -7.18%
Upper Bollinger Band Walk Strength -7.18%
Weak + Overbought Other -7.18%

   Recent Intraday Alerts

Alert Time
Down 5% about 20 hours ago
Down 1 ATR about 20 hours ago
Down 3% about 20 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioLineRx Ltd. Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pain Infectious Diseases Clinical Development Autoimmune Disease Drug Discovery Acute Myeloid Leukemia Pharmacology Clinical Research Clinical Trial Schizophrenia Inflammatory Bowel Disease Nerve Neuropathic Pain Treatment Of Acute Myeloid Leukemia Central Nervous System Disease Hematological Cancers Pivotal Compugen Biopharmaceutical Development Treatment Of Inflammatory Bowel Disease Infarction Myocardial Infarction Polymer Solution

Is BLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

S

SociableGnat503 11 months ago

For the trading Czars here, if I owned 8,000 shares at 1.41 with a target PDUFA date of 09/09/2023.  How would you play this going forward based on the technicals/fundamentals? 

0 Reply
S

SociableGnat503 11 months ago

Does this show any particular trend? 

0 Reply
T

TraderMike 11 months ago

This is what the trend table on the stock's page tells you.  Here's the current TT for BLRX:
BLRX_trend_table.png 56.8 KB
Those are based on the 200, 50 & 10 day moving averages.  You can also choose some other moving average that matches your timeframe & check if the stock is above or below that MA.  If it's above, then the trend is up, if it's below, the trend is down.

There are other ways to determine trend but moving averages are a pretty good & simple way to get a quick read.

1 Reply
T

TearfulSnail334 9 months ago

Can I ask here:  How can I change the Moving Averages as stated above.  I like the 20 instead of the 10

1 Reply
T

TraderMike 9 months ago

Sorry, those aren’t configurable 

0 Reply
S

SociableGnat503 10 months ago

Any thoughts on the current action.  I can't understand biotech for the life of me.  FDA approved product, well financed, and deep pipeline ....and it's trading below what it was before approval.  

0 Reply
T

TraderMike 10 months ago

Not making any sense sounds about right for a small biotech stock. 😁  A few things come to mind:

  1. Looks like a classic "buy the rumor, sell the news(fact)" situation.
  2. There's tons of overhead supply.  So it could just be sellers who've been sitting on losses for who knows how long using the recent pop as an opportunity to get out.
  3. We're in a "risk off" market right now.  The more speculative the stock, the more likely it is to be dumped.
Any of those or a combination could be to blame.  

1 Reply
S

SociableGnat503 11 months ago

It looks like the short, intermediate, and long term trends look better now! It seems to be a late bloomer with a PDUFA decision on the horizon. 

0 Reply
S

SarcasticTurtle143 10 months ago

Lot other bios got approvals have the same issue.  Bio is completely slaughtered not sure when will it rise from the ashes inspite of M&A. IMHO. I am long term bio investor. Please do you DD.  Good Luck..

1 Reply

View full discussion...

Indicators

Indicator Value
52 Week High 2.53
52 Week Low 0.51
Average Volume 336,576
200-Day Moving Average 1.12
50-Day Moving Average 0.65
20-Day Moving Average 0.63
10-Day Moving Average 0.69
Average True Range 0.06
RSI (14) 65.03
ADX 28.66
+DI 33.53
-DI 8.17
Chandelier Exit (Long, 3 ATRs) 0.70
Chandelier Exit (Short, 3 ATRs) 0.70
Upper Bollinger Bands 0.83
Lower Bollinger Band 0.43
Percent B (%b) 0.91
BandWidth 62.11
MACD Line 0.04
MACD Signal Line 0.01
MACD Histogram 0.0322
Fundamentals Value
Market Cap 57.22 Million
Num Shares 72.4 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -1.05
Price-to-Sales 0.00
Price-to-Book 6.01
PEG Ratio 0.20
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.95
Resistance 3 (R3) 0.97 0.93 0.93
Resistance 2 (R2) 0.93 0.89 0.92 0.92
Resistance 1 (R1) 0.86 0.86 0.84 0.84 0.91
Pivot Point 0.82 0.82 0.81 0.81 0.82
Support 1 (S1) 0.75 0.78 0.73 0.74 0.67
Support 2 (S2) 0.71 0.75 0.70 0.66
Support 3 (S3) 0.64 0.71 0.65
Support 4 (S4) 0.63